GST-HG141

DRUG4 trials

Sponsors

Fujian Akeylink Biotechnology Co., Ltd.

Conditions

Chronic Hepatitis BChronic Hepatitis b

Phase 2

Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets

CompletedNCT05637541

Fujian Akeylink Biotechnology Co., Ltd.Chronic Hepatitis b

Start: 2023-01-03End: 2024-08-24Updated: 2025-03-05

Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B

RecruitingNCT07709520

Fujian Akeylink Biotechnology Co., Ltd.Chronic Hepatitis B

Start: 2026-07-10End: 2026-12-01Target: 80Updated: 2026-07-17

Phase 3

To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment

RecruitingNCT07090759

Fujian Akeylink Biotechnology Co., Ltd.Chronic Hepatitis b

Start: 2025-07-24End: 2027-03-01Target: 526Updated: 2026-01-23

Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B

Not yet recruitingNCT07588009

Fujian Akeylink Biotechnology Co., Ltd.Chronic Hepatitis b

Start: 2026-06-26End: 2028-03-01Target: 576Updated: 2026-05-14

Related Papers

Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study.

2025-08-021 citations